Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial

Slides:

Advertisements

Similar presentations

The PSA Era is not Over for Prostate Cancer

Advertisements

Volume 50, Issue 1, Pages (July 2006)

Volume 52, Issue 1, Pages (July 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 4, Pages (October 2010)

Testosterone Therapy in Men With Prostate Cancer

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 53, Issue 4, Pages (April 2008)

Volume 73, Issue 6, Pages (June 2018)

Volume 51, Issue 4, Pages (April 2007)

Volume 69, Issue 1, Pages (January 2016)

Volume 65, Issue 5, Pages (May 2014)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Prostate Cancer Epidemic in Sight?

Volume 63, Issue 2, Pages (February 2013)

Volume 74, Issue 4, Pages (October 2018)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

Volume 74, Issue 1, Pages (July 2018)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 54, Issue 4, Pages (October 2008)

Elizabeth K. Bancroft, Rosalind A. Eeles

Volume 63, Issue 6, Pages (June 2013)

Volume 53, Issue 4, Pages (April 2008)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Detection: A View of the Future

Volume 54, Issue 5, Pages (November 2008)

Volume 68, Issue 3, Pages (September 2015)

Volume 67, Issue 3, Pages (March 2015)

Volume 56, Issue 2, Pages (August 2009)

Volume 66, Issue 3, Pages (September 2014)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 67, Issue 6, Pages (June 2015)

Volume 64, Issue 6, Pages (December 2013)

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 2, Pages (February 2008)

Volume 74, Issue 3, Pages (September 2018)

Volume 58, Issue 5, Pages (November 2010)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Volume 53, Issue 4, Pages (April 2008)

Volume 58, Issue 1, Pages 1-7 (July 2010)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Volume 74, Issue 2, Pages (August 2018)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 50, Issue 5, Pages (November 2006)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Volume 15, Issue 4, Pages (April 2014)

Volume 71, Issue 5, Pages (May 2017)

Volume 67, Issue 6, Pages (June 2015)

Volume 53, Issue 1, Pages (January 2008)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 59, Issue 4, Pages (April 2011)

Volume 70, Issue 1, Pages (July 2016)

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 74, Issue 6, Pages (December 2018)

Volume 53, Issue 6, Pages (June 2008)

Management of Prostate Cancer: Global Strategies

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis Sarah Burdett, Liselotte M. Boevé,

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Volume 54, Issue 1, Pages (July 2008)

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer Alex P. Hoyle, Adnan Ali, Nicholas D. James, Adrian Cook, Christopher.

Presentation transcript:

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial Antoine Kass-Iliyya, Gordana Jovic, Claire Murphy, Cyril Fisher, Isabel Syndikus, Chakiath Jose, Christopher D. Scrase, John D. Graham, David Nicol, Matthew R. Sydes, David Dearnaley European Urology Volume 73, Issue 6, Pages 968-976 (June 2018) DOI: 10.1016/j.eururo.2017.12.017 Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 1 CONSORT diagram. bPFS=biochemical progression-free survival; LB=local histopathology review 2-yr biopsy; MFS=metastasis-free survival; OS=overall survival; PCa=prostate cancer; RT=radiotherapy. a 1 patient satisfies both criteria. b 1 patient satisfies both criteria. European Urology 2018 73, 968-976DOI: (10.1016/j.eururo.2017.12.017) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 2 Outcome measures, per-protocol (PP) group (central review). (A) Biochemical progression-free survival (bPFS), by biopsy outcome. (B) bPFS, negative and suspicious versus positive biopsy. (C) Metastases-free survival (MFS), by biopsy outcome. (D) MFS, negative and suspicious versus positive biopsy. (E) Overall survival (OS), by biopsy outcome. (F) OS, negative and suspicious vs positive biopsy. European Urology 2018 73, 968-976DOI: (10.1016/j.eururo.2017.12.017) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 3 Time from 2-yr prostate-specific antigen (PSA) test to (A) PSA failure, (B) biochemical progression-free survival (bPFS) event, (c) metastasis-free survival (MFS) event, (D) prostate cancer (PC)-related death, (E) death; 2-yr PSA population. European Urology 2018 73, 968-976DOI: (10.1016/j.eururo.2017.12.017) Copyright © 2017 European Association of Urology Terms and Conditions